Last reviewed · How we verify

ICLAPRIM — Competitive Intelligence Brief

ICLAPRIM (ICLAPRIM) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: iclaprim. Area: Infectious Disease.

discontinued iclaprim Dihydrofolate reductase, Dihydrofolate reductase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

ICLAPRIM (ICLAPRIM). ICLAPRIM works by inhibiting the enzyme dihydrofolate reductase, which is essential for bacterial DNA synthesis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ICLAPRIM TARGET ICLAPRIM discontinued iclaprim Dihydrofolate reductase, Dihydrofolate reductase
EDATREXATE EDATREXATE marketed edatrexate Folylpolyglutamate synthase, mitochondrial, Dihydrofolate reductase, Dihydrofolate reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (iclaprim class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ICLAPRIM — Competitive Intelligence Brief. https://druglandscape.com/ci/iclaprim. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: